Nanoparticles for cardiovascular imaging: Stendahl and Sinusas provide the second of 2 overviews, here describing current examples of radiolabeled nanoparticulate probes for PET and SPECT and their utility in a range of preclinical cardiac applications.
Page 1637
Tumor texture analysis and PET: Buvat and colleagues offer perspectives on current image analysis approaches and areas for needed advancement in PET characterization of tumor heterogeneity.
Page 1642
Innervation–MBF and 11C-HED PET: Dilsizian and Eckelman look at challenges associated with using a single radioisotope in PET assessment of both myocardial blood flow and innervation and preview an article on this topic in this issue of JNM.
Page 1645
177Lu-octreotate for pancreatic NETs: van Vliet and colleagues describe outcomes of neoadjuvant treatment of pancreatic neuroendocrine tumors with peptide receptor radionuclide therapy in patients with borderline unresectable or oligometastatic disease.
Page 1647
Predicting 90Y microsphere outcomes: Ilhan and colleagues analyze the predictive value of 99mTc-MAA SPECT for 90Y-labeled resin microsphere radioembolization in primary and secondary liver malignancies by comparing uptake on pretherapeutic 99mTc-MAA SPECT with that on posttherapeutic 90Y SPECT.
Page 1654
18F-FEC PET/CT in radioembolization: Hartenbach and colleagues evaluate 18F-fluoroethylcholine PET/CT as a metabolic imaging technique for assessment of treatment response to 90Y radioembolization in patients with locally advanced hepatocellular carcinoma.
Page 1661
Texture features in PET: Yan and colleagues explore the effect of image reconstruction settings on more than 50 separate texture parameters in 18F-FDG PET images acquired on a PET/CT scanner incorporating point-spread function and time-of-flight technology.
Page 1667
PET/CT for breast cancer staging: Hogan and colleagues identify differences in 18F-FDG PET/CT systemic staging in women newly diagnosed with invasive lobular carcinoma and those with invasive ductal carcinoma.
Page 1674
PET/CT, early response, and breast cancer: Kostakoglu and colleagues determine whether an early change in 18F-FLT standardized uptake values using PET with CT can predict pathologic complete response of primary breast cancer to neoadjuvant chemotherapy.
Page 1681
Modulating NIS function in ATC cells: Singh and colleagues investigate the role of estrogen-related receptor γ in regulation of sodium iodide symporter function in anaplastic thyroid cancer cells using GSK5182, an inverse agonist of estrogen-related receptor γ.
Page 1690
68Ga-PSMA-617 in prostate cancer diagnosis: Afshar-Oromieh and colleagues detail the biodistribution of this prostate-specific membrane antigen–targeted PET radioligand in normal tissues and in prostate cancer and report on radiation exposure with the agent in PET imaging.
Page 1697
Innervation–MBF mismatch and 11C-HED: Harms and colleagues assess the rate of tracer influx from blood to myocardium on an 11C-HED PET scan as an index of myocardial blood flow, with potential for identifying areas of blood flow–innervation mismatch.
Page 1706
SPECT MPR in multivessel CAD: Ben Bouallègue and colleagues describe the feasibility of myocardial perfusion reserve estimation using a cadmium-zinc-telluride camera in a cohort of patients with multivessel coronary artery disease and correlate results with invasive angiographic data.
Page 1712
V/Q PET/CT in lung function: Le Roux and colleagues compare quantitative ventilation/perfusion PET/CT results and pulmonary function test data, with results that support the use of V/Q PET/CT in radiation therapy, preoperative planning, and pulmonary dysfunction assessment.
Page 1718
nAChR availability and nicotine metabolism: Dubroff and colleagues use 2-18F-FA PET to examine the relationship between nicotine metabolite ratio, a stable measure of hepatic nicotine metabolism, and nicotinic acetylcholine availability in smokers characterized as slow and normal metabolizers.
Page 1724
Cerebral 11C-laniquidar kinetics: Froklage and colleagues develop a pharmacokinetic model for quantification of uptake of this newly developed tracer of P-glycoprotein expression and assess its test–retest variability in healthy subjects.
Page 1730
18F-florbetapir PET quantification: Joshi and colleagues describe a semiautomated quantitative method for estimating 18F-florbetapir plaque binding using static 10-min PET images, evaluate the method’s accuracy, and compare derived standardized uptake value ratios with neuropathologic amyloid measures.
Page 1736
BAT/WAT discrimination with PET/MR: Franz and colleagues evaluate signal-fat-fraction analysis based on a 2-point-Dixon water–fat separation method in whole-body simultaneous PET/MR imaging for distinguishing brown adipose tissue from white adipose tissue.
Page 1742
90Y-DOTATOC in meningioma treatment: Gerster-Gilliéron and colleagues investigate whether somatostatin receptor–targeted radionuclide therapy with 90Y-DOTATOC may be an option in meningioma patients with recurrent or progressive meningiomas.
Page 1748
Molecular imaging in radiotherapy: Jeraj and colleagues provide an educational overview of molecular imaging applications in radiation therapy, with a focus on target definition, treatment response assessment, quantitative imaging requirements, potential limitations, and possibilities for future development.
Page 1752
211At RIT optimized mAb dose: Frost and colleagues report on optimization of the anti-CD45 monoclonal antibody protein dose for 211At radioimmunotherapy in hematopoietic cell transplantation, including tracer activity distribution and α-imaging–based small-scale dosimetry.
Page 1766
Enhancing SC therapy in brain injury: Zhang and colleagues use spatiotemporal PET to investigate metabolic changes after combined therapy with induced pluripotent stem cells, neuronal stem cells, and Chinese patent medicine in a rat model of cerebral ischemia–reperfusion injury.
Page 1774
PET and PTK7 expression: Jacobson and colleagues describe the development of a specific, selective, and high-affinity PET radioligand based on a single-stranded DNA aptamer to address challenges in noninvasively visualizing tumoral expression of protein tyrosine kinase-7.
Page 1780
Hyperpolarized 13C-pyruvate and 18F-FDG PET: Gutte and colleagues establish a practical workflow for tumor tissue characterization with simultaneous 18F-FDG PET and hyperpolarized 13C-pyruvate MR spectroscopy and test its feasibility in dogs with cancer.
Page 1786
Intraarterial microdosing and PET: Burt and colleagues describe 18F-FDG PET assessment of preclinical studies evaluating a novel drug development approach combining intraarterial drug delivery and microdosing.
Page 1793
Biodistribution of 131I-tositumomab: Wahl and colleagues investigate whether altered biodistribution of 131I-tositumomab can be identified using quantitative calculations of whole-body residence time alone for decision making about administration of therapeutic doses.
Page 1800
- © 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Jump to section
Related Articles
Cited By...
- No citing articles found.